In summary, our research demonstrated that USP36 promotes the aggressiveness, chemoresistance, and metastasis of colon cancer by deubiquitinating and stabilizing c-Myc, and uncovered a potential USP36 inhibitor, CBF, in the treatment of colon cancer. This evidence concerns the gene CEBPZ and malignant colon neoplasm.